Your browser doesn't support javascript.
loading
Healthcare utilization and unmet needs of patients with antisynthetase syndrome: An international patient survey.
Weiss, M; Holzer, M T; Muehlensiepen, F; Ignatyev, Y; Fiehn, C; Bauhammer, J; Schmidt, J; Schlüter, S; Dihkan, A; Scheibner, D; Schneider, U; Valor-Mendez, L; Corte, G; Gupta, L; Chinoy, H; Lundberg, I; Cavagna, L; Distler, J H W; Schett, G; Knitza, J.
Affiliation
  • Weiss M; Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
  • Holzer MT; Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University, Erlangen, Germany.
  • Muehlensiepen F; III. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. m.holzer@uke.de.
  • Ignatyev Y; Faculty of Health Sciences, Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany.
  • Fiehn C; Faculty of Health Sciences, Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany.
  • Bauhammer J; Praxis für Rheumatologie, Klinische Immunologie, Medical Center, Baden-Baden, Germany.
  • Schmidt J; Praxis für Rheumatologie, Klinische Immunologie, Medical Center, Baden-Baden, Germany.
  • Schlüter S; Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany.
  • Dihkan A; Department of Neurology and Pain Treatment, Center for Translational Medicine, Neuromuscular Center, Immanuel Klinik Rüdersdorf, University Hospital of the Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany.
  • Scheibner D; Department of Neurology, Neuromuscular Center, University Medical Center, Göttingen, Germany.
  • Schneider U; Myositis-Gruppe, Deutsche Gesellschaft Für Muskelkranke, Freiburg, Germany.
  • Valor-Mendez L; The Swedish Working Group for Myositis, The Swedish Rheumatism Association, Stockholm, Sweden.
  • Corte G; Myositis-Gruppe, Deutsche Gesellschaft Für Muskelkranke, Freiburg, Germany.
  • Gupta L; Department of Rheumatology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Chinoy H; Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
  • Lundberg I; Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University, Erlangen, Germany.
  • Cavagna L; Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
  • Distler JHW; Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University, Erlangen, Germany.
  • Schett G; Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.
  • Knitza J; Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK.
Rheumatol Int ; 43(10): 1925-1934, 2023 10.
Article in En | MEDLINE | ID: mdl-37452880
ABSTRACT
Antisynthease syndrome (ASSD) is a rare, complex and understudied autoimmune disease. Internet-based studies can overcome barriers of traditional on-site research and are therefore very appealing for rare diseases. The aim of this study was to investigate patient-reported symptoms, diagnostic delay, symptoms, medical care, health status, working status, disease knowledge and willingness to participate in research of ASSD patients by conducting an international web-based survey. The multilingual questionnaire was created by an international group of rheumatologists and patients and distributed online. 236 participants from 22 countries completed the survey. 184/236 (78.0%) were female, mean age (SD) was 49.6 years (11.3) and most common antisynthetase antibody was Jo-1 (169/236, 71.6%). 79/236 (33.5%) reported to work full-time. Median diagnostic delay was one year. The most common symptom at disease onset was fatigue 159/236 (67.4%), followed by myalgia 130/236 (55.1%). The complete triad of myositis, arthritis and lung involvement verified by a clinician was present in 42/236 (17.8%) at disease onset and in 88/236 (37.3%) during the disease course. 36/236 (15.3%) reported to have been diagnosed with fibromyalgia and 40/236 (16.3%) with depression. The most reported immunosuppressive treatments were oral corticosteroids 179/236 (75.9%), followed by rituximab 85/236 (36.0%). 73/236 (30.9%) had received physiotherapy treatment. 71/236 (30.1%) reported to know useful online information sources related to ASSD. 223/236 (94.5%) were willing to share health data for research purposes once a year. Our results reiterate that internet-based research is invaluable for cooperating with patients to foster knowledge in rare diseases.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Autoantibodies / Myositis Type of study: Diagnostic_studies Limits: Female / Humans / Male / Middle aged Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Autoantibodies / Myositis Type of study: Diagnostic_studies Limits: Female / Humans / Male / Middle aged Language: En Year: 2023 Type: Article